P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice
نویسندگان
چکیده
منابع مشابه
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Randomized controlled trials examining the efficacy or safety of vedolizumab in patients with IBDs ...
متن کاملVedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.
BACKGROUND Vedolizumab (VDZ) is a humanised monoclonal IgG1 antibody targeting α4 β7 integrin. AIM To investigate the real-world efficacy of vedolizumab for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). METHODS A consecutive cohort of 212 adult IBD patients with active disease (HBI >7/partial Mayo >4) newly receiving VDZ was prospectively recruited from 7 academic and 1...
متن کاملEfficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease
We sought to evaluate the safety and efficacy of available biologics that inhibit T-cell migration by blocking a4b7 integrins in inflammatory bowel diseases. The aim of this study is to evaluate whether Crohn disease (CD) patients receiving either vedolizumab or natalizumab have any different effect in CD Activity Index (CDAI). Using Medline, Excerpta Medica dataBASE, Cochrane Central Register ...
متن کاملDesigning biologic selectivity for inflammatory bowel disease – role of vedolizumab
Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate re...
متن کاملVedolizumab for the treatment of inflammatory bowel disease.
The causes of inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD), remain to be elucidated. However, characteristic inflammation of the gastrointestinal mucosa is caused by infiltration of T lymphocytes into the submucosal layer. Inhibiting this immune response is a promising therapeutic target. Integrins expressed on the cell surface mediate gut homing of T ly...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammatory Bowel Diseases
سال: 2016
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000480124.51296.b7